机构:[1]Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.[2]Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China.[3]Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.[4]Department of Respiratory and Critical Care Medicine, Provincial Clinical Research Center for Respiratory Diseases, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[5]National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610065, China.[6]Cancer Center, Zhejiang University, Hangzhou 310029, China.
Classical chemotherapeutic drugs may cause immunogenic cell death (ICD), followed by activating CD8+ T cells to promote cell-mediated antitumor immune responses. However, CD8+ T cells become exhausted due to tumor antigens' continuous stimulation, creating a major obstacle to effectively suppressing tumor growth and metastasis. Here, we develop an approach of chemo-gene combinational nanomedicine to bridge and reprogram chemotherapy and immunotherapy. The dually loaded nanomedicine induces ICD in tumor cells through doxorubicin and reverses the antitumor effects of exhausted CD8+ T cells through the small interfering RNA. The synergistic chemo-gene and fluorine assembly nanomedicine enriched in reactive oxygen species and acid-sensitive bonds results in enhanced cancer immunotherapy to inhibit tumor growth and the lung metastasis of breast cancer in a mouse model of breast cancer and melanoma. This study provides an efficient strategy and insights into chemoimmunological cascade therapy for combating malignant metastatic tumors.
基金:
National Key R&D Program of China
(2022YFE0121600 and 2022YFC3401600), the National
Natural Science Foundation of China (22277107 and
82188102), the Natural Science Foundation of Zhejiang
Province (LZ21H160002), and Fundamental Research Funds
for the Central Universities of China (226-2022-00168).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|1 区材料科学
小类|1 区化学:综合1 区物理化学1 区材料科学:综合1 区纳米科技
最新[2023]版:
大类|1 区材料科学
小类|1 区化学:综合1 区物理化学1 区材料科学:综合1 区纳米科技
第一作者:
第一作者机构:[1]Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.[2]Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China.
通讯作者:
通讯机构:[1]Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.[2]Institute of Translational Medicine, Zhejiang University, Hangzhou 310029, China.[6]Cancer Center, Zhejiang University, Hangzhou 310029, China.[*1]Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China[*2]Institute of Translational Medicine and Cancer Center, Zhejiang University, Hangzhou 310029, China
推荐引用方式(GB/T 7714):
Zhang Qingyan,Wu Pengkai,Wu Jicheng,et al.Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine[J].ACS nano.2023,17(8):7498-7510.doi:10.1021/acsnano.2c12600.
APA:
Zhang Qingyan,Wu Pengkai,Wu Jicheng,Shou Hao,Ming Xinliang...&Wang Ben.(2023).Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine.ACS nano,17,(8)
MLA:
Zhang Qingyan,et al."Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine".ACS nano 17..8(2023):7498-7510